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INTRODUCTION
Malignant bone tumors like osteosarcoma and Ewing sarcoma
mostly appear during the teenage years in the long bones of the
lower extremity. The survival rates for children and adolescents with
lower extremity sarcoma have improved remarkably over the past
decades. Several options for surgical intervention have become
available, including limb salvage by allograft or endoprosthetic
reconstruction, amputation as well as rotationplasty [1]. As long as
wide, tumor-free tissue margins are achieved by resection, and
appropriate chemotherapy is administered, patient survival and
local tumor recurrence do not depend on the type of surgery [2]. As a
result of the improved life expectancy, there has been a growing
interest in functional outcome and Health Related Quality of Life
(HRQoL) after surgery [3–10]. Most of the studies on the outcome
of surgery for malignant bone tumors were mainly focused on basic
daily activities or used generic instruments for QoL. In these
instruments, a number of relevant issues, such as the patient’s
valuation of his or her life after the disease and its surgical treatment
are not specifically taken into account. Since bone tumor surgery
may have considerable consequences within the domains physical
activity and sports, body image, and cosmetic appearance [8], it is
important to include these domains in instruments concerning QoL
in persons who underwent surgery for malignant bone tumors.
For this reason, a specific bone tumor version (Bt-DUX) of an
existing quality of life (QoL) instrument, the DUX-25 [10–25], was
developed. The disease-specific Bt-DUX is based on the generic
DUX-25 questionnaire [11]. The generic DUX-25 assesses the
influence of a disease on daily activities. It contains 25 items within
four different domains: social, emotional, physical, and home
functioning. The scoring of the items is done by abstract faces with
varying expressions (smiley’s), ranging from very happy to sad. The
DUX-25 has been used in studies among siblings of pediatric cancer
patients [14], children with celiac disease [13–15], juvenile chronic
Background. To examine the practical applicability, internal
consistency, and validity of the Bt-DUX, a disease-specific Health
Related Quality of Life (HRQoL) instrument. The Bt-Dux was
developed to examine patients’ individual values of their life after
a malignant bone tumor of the lower extremity at four domains
(cosmetic, social, emotional, and functional). Procedure. Patients
were eligible for this cross-sectional, multicenter study if they
underwent surgery for a malignant tumor of the leg in a period
ranging between 12 and 60 months before the recruitment. Assess-
ments included: Bt-DUX, Toronto Extremity Salvage Score (TESS)
Short Form (SF)-36, TNO-AZL Questionnaire for Adult’s Quality of
Life (TAAQOL), and TNO-AZL Children’s Quality of Life Question-
naire (TACQOL). Results. Seventy-two patients (35 male, 37 female),
mean age 17 (SD 4) years were included. Limb sparing surgery took
place in 32 patients and ablative surgery in 40 patients. The Bt-DUX
was completed in less than 5 min and easy to comprehend. The
mean Bt-DUX score was 69.8 (SD 15.5), with Cronbach’s alpha
being 0.92. Domain–total correlations ranged between 0.84 and
0.88 (P<0.01). Correlations between Bt-DUX Total score and TESS,
SF-36 Physical and Mental Component Summary scales and selected
TACQOL and TAAQOL scores were statistically significant
(P< 0.05), except for the social scale of the TACQOL. The Bt-DUX
was able to discriminate between patients with higher and lower
TESS scores (P<0.05). Conclusion. The Bt-DUX was found to be a
practical and valid instrument. Its added value compared with
existing HRQoL measures needs to be further established. Pediatr
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arthritis [11], malignant bone tumors [10], and proved to be
internally consistent and reproducible in all studies.
The purpose of the present study is to examine the practical
applicability, internal consistency, and validity of the Bt-DUX for
patients with a malignant bone tumor in the lower extremity.
PATIENTS AND METHODS
Study Design and Patient Recruitment
This cross-sectional study included all patients who underwent a
surgical intervention due to a malignant bone tumor in the lower
extremity in five university medical centers. Patients were identified
through hospital records. Patients were eligible if they were aged
between 8 and 25 years at the time of the selection, if the time since
surgery ranged between 12 and 60 months, if the malignant bone
tumor (osteosarcoma or Ewing’s sarcoma) was located around the
knee and the surgical intervention consisted of limb sparing or
ablative surgery. The minimum duration since surgery of 12 months
was chosen to minimize the impact of the medical treatment and its
complications and resulting mental consequences on physical
functioning and QoL. Patients were excluded if medical conditions
other than the bone tumor and its treatment limited physical
activities. The selection took place between 2004 and 2006. The
Medical Ethics Committee approved the study and all patients and/
or their parents gave informed consent.
Development of the Bt-DUX
For the construction of the Bt-DUX, 10 questions of the DUX-
25, which were considered to be relevant for patients with bone
tumors, were selected. The remaining overlap with questions in
other disease-specific versions of the DUX would enable compar-
isons with other patient populations. After interviewing 10 patients
(aged between 10 and 19 years) and 4 experienced colleagues
(physical therapist, psychologist, and 2 pediatric oncologists),
10 questions were added. These questions specifically addressed
functional limitations and cosmetic changes as a result of the
surgical intervention. All patients and colleagues were from the
Leiden University Medical Center. The principle investigator
(WPB) presented a draft version, whereupon a final selection of
20 questions was made by the four experts. Similar to the generic
DUX-25, the scoring of the items is done by abstract faces with
varying expressions/smiley’s (see Supplemental Figure), ranging
from very happy (score 1) to sad (score 5). The raw item scores are
converted into total and domain scores, ranging from 0 to 100, with
the highest scores indicating better HRQoL.
Assessment Methods
The practical applicability of the Bt-DUX was evaluated by
interviewing 20 patients after completing the questionnaire
with respect to the following aspects: completion in less than
5 min (yes/no) and whether the questions and answer categories
were easy to comprehend (yes/no). Moreover, the rate of missing
answers was determined for every question.
Clinical and Demographic Characteristics
Patient’s clinical and demographic data were retrieved from
registries and medical records. These data comprised: age (years),
sex (male/female), type of sarcoma, location and side of the tumor,
and type of surgery. In addition to the Bt-DUX, all patients received
the Toronto Extremity Salvage Score (TESS) [16]. Children under
16 years of age received the TNO-AZL Children’s Quality of Life
Questionnaire (TACQOL) [17–19] whereas patients aged 16 years
and older received the TNO-AZL Questionnaire for Adult’s Quality
of Life (TAAQOL) [20] and the Short Form-36 (SF-36) [21]. All
patients were asked to complete the questionnaires by themselves.
The SF-36 [21] is a validated, self-administered measure of
HRQoL. The SF-36 evaluates eight health concepts or domains:
physical functioning, role limitation due to physical problems
(role–physical), bodily pain, general perception of health,
vitality, social function, role limitation due to emotional problems
(role—emotional), and mental health. Each scale score ranges from
0 (worst health state) to 100 (best health state). These eight health
concept scales can be converted into a Physical Component
Summary (PCS) and a Mental Component Summary scale
(MCS), standardized to a score with a mean of 50 and a standard
deviation of 10, with scores above and below 50 indicating above
and below average functioning, respectively. For that purpose, we
used the scores from an age- and sex-matched, normative sample,
drawn from a large, random, nationwide sample of adults
(N¼ 1742) from the general Dutch population [21].
The TACQOL questionnaire [17–19] was developed as a generic
instrument intended for HRQoL assessment for children aged 8–
16 years old and validated in a Dutch population. The TACQOL
contains 57 questions, divided over seven scales of eight items
each; physical complaints, motor functioning, autonomy, cognitive
functioning, social functioning, negative, and positive emotions.
The score ranges were 0–4 per item and 0–100 per scale, with
higher scores representing better HRQoL. Reliability of the scales
was found to be sufficient for research purposes, with Cronbach’s
alpha’s ranging from 0.66 to 0.79 [17].
TAAQOL questionnaire [20] is a validated, generic HRQoL
questionnaire for persons of 16 years and older. The TAAQOL
consists of 45 questions divided into 12 scales (most of them four
items each): gross motor functioning, fine motor functioning,
cognition, sleep, pain, social contacts, daily activities, sex, vitality,
happiness, depressive mood, and anger. The TAAQOL question-
naire measures the emotional impact of self-reported functional
problems in the same way as the TACQOL does. Internal consis-
tency of the scales was found sufficient for research purposes [20].
The TESS [16] is a validated and reliable disease-specific
measure developed to evaluate physical disability in patients treated
for extremity sarcoma. The self-administered questionnaire
includes 30 items on activity limitations in daily life, such as
restrictions in body movement, mobility, self-care, and performance
of daily tasks and routine. The degree of physical disability is rated
from 0 (not possible) to 5 (without any problem). The raw score is
converted to a score ranging from 0 to 100 points, with higher scores
indicating less functional limitations.
Statistical Analysis
Initial descriptive analyses were performed on all variables.
Total and domain scores of all variables were examined to ascertain
the data distribution and assess normality. Depending on the data
distribution, tests for data with normal distribution (ANOVA and
independent samples t-test) or skewed distribution (Spearman
correlation coefficients) were applied.
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The Bt-Dux Total score and domain scores were compared
among the patients undergoing allograft reconstruction, endopros-
thetic replacement, rotationplasty, or amputation by means of
analysis of variance (ANOVA).
Internal consistency of the Bt-DUX was determined by
calculating Cronbach’s a and by computing the correlation between
the four domain scores and the total Bt-DUX score (domain–total
correlation). A Cronbach’s a value of 0.85 was considered as good
[22]. In order to evaluate the preconceived domain structure of the
Bt-DUX, an analysis of the item–domain correlation and the
Cronbach’s a of the four domains was performed.
In the absence of a gold standard for QoL and its valuation in
patients with a malignant bone tumor, we determined the construct
validity of the Bt-Dux by computing associations with various other
disease-specific and generic measures of QoL (previously selected
subscales of the TAAQOL, TACQOL, and SF-36) or daily func-
tioning (TESS). We hypothesized that the strength of the
correlations between Bt-DUX and other measures would vary
between moderate (between 0.3 and 0.5) and large (between 0.5 and
0.7) [23–24]. Associations exceeding the 0.7 (very large) could
point in the direction of overlap between the Bt-DUX and the other
instruments, and thus limit its added value.
Discriminate validity was evaluated by comparing Bt-DUX
values between patients with worse and better function as
categorized according to the median value of the functional
outcome measure (TESS score).
RESULTS
Characteristics of the Patients
Between 2003 and 2005, one hundred four patients who
underwent surgery for a malignancy of the lower extremity were
identified from the registries of the five participating university
hospitals and fulfilled the inclusion criteria. Of these patients,
22 died before the evaluation, the physical and mental condition of
one patient did not allow for participation, two patients lived abroad
and four refused participation for other reasons. The questionnaires
of three patients were not complete and therefore left out of the
analysis. Finally, seventy-two patients were included. Table I
provides their clinical demographic characteristics. With respect to
the type of surgery, patients were classified into either the limb
sparing or the ablative surgery group. Rotationplasty was classified
as an ablative form of surgery, because of the dependency on limb
prosthesis and the cosmetic consequences compared to allograft or
endoprosthetic replacements.
Practical Applicability and Characteristics of the
Bt-DUX and Domain Scores
All 20 patients who were interviewed about the practical
applicability reported that both question and answer categories were
easy to understand and all were able to complete the questionnaire in
less than 5 min. Except for the question ‘‘getting boy/girlfriend/
relationship’’ (missing value in six patients, 8%), all questions were
completed by all 72 patients.
Table II shows the results of the Bt-DUX, and Table III shows the
results of the other measures of QoL and functional ability. Figure 1
shows the mean and median scores and the distribution of Bt-DUX
total and domain scores. The mean Bt-DUX total score and
its individual domain scores varied between 50.2 and 80.9. The
Bt-DUX total and most of the domain scores were distributed
normally [22], except for the score on the social domain; this score
had a skewed distribution, with 21% of the patients reporting
maximal appreciation. The lowest domain score was obtained
for the domain physical. There were no statistical differences of the
Bt-Dux Total score and domain scores among patients who
underwent allograft reconstruction, endoprosthetic replacement,
rotationplasty, or amputation.
The mean score of 85.3 (SD 12.2) for the TESS indicates
moderate functional limitations. The mean scores of the SF-36 were
35.3 (SD 13.9) for the Physical Component and 55.8 (SD 13.6) for
the Mental Component Summary scales mean TAAQOL and
TACQOL domain scores varying between 62.4 and 89.9 indicate a
reasonable level of HRQoL in our population.
Table IV shows the raw mean and median scores of the Bt-DUX
on the different item levels. Here, the lowest appreciation scores
were obtained for the items: ‘‘the amount of sports I can do,’’ ‘‘my
abilities in sports,’’ ‘‘my stamina,’’ ‘‘people looking at me’’ (median
value 3¼ ordinary, range 1–5) and ‘‘the things I can’t do’’ (median
value 4¼ rather sad, range 1–5).
Three of the items within the social and emotional domain:
‘‘with me it’s going,’’ ‘‘making new fiends,’’ and ‘‘about my
friends’’ showed median scores at the highest appreciation level
(1¼ very happy; range 1–3). Fifteen of the 20 items displayed the
full range of reported scores from 1 to 5.
Internal Consistency
The internal consistency of total and domain scores of the Bt-
DUX appeared to be good. Cronbach’s a was 0.92 for the total Bt-
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TABLE I. Clinical and Demographic Characteristics of 72
Patients Who Underwent Surgical Treatment for a Malignant
Bone Tumor of the Lower Extremity
No. of patients
(%) Mean SD Range
Gender
Female 37 (51%)
Male 35 (49%)
Age (years)
At evaluation 17 4 8–25
At surgery 14 4 3–24
Follow-up 3 2 1–5
Age group
Children 30 13 2 8–16
Adolescents 42 20 3 16–25
Type of surgery
Limb sparing 32 (44%)
Allograft 22 (31%)
Prosthesis 10 (14%)
Ablative 40 (55%)
Amputation 25 (35%)
Rotationplasty 15 (21%)
Morphology
Osteosarcoma 58 (81%)
Ewing’s sarcoma 14 (19%)
Tumor location
Femur 47 (65%)
Tibia/fibula 25 (35%)
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DUX, 0.73 for the emotional and cosmetics, 0.77 for the social and
0.82 for the physical function domain scores. The domain–total
correlations appeared to be good, with Spearman correlation
coefficients varying between 0.85 and 0.89 (P< 0.01). The item–
domain correlation was moderate, with Spearman correlation
coefficients varying between 0.58 and 0.88 (P< 0.01).
Construct Validity
The results of the validity statistics are presented in Table V. The
Bt-DUX demonstrates a moderate-to-strong relationship with the
other measures at the domain of QoL.
The Bt-DUX total score was moderately associated with the
TACQOL and TAAQOL. Spearman correlations coefficients
between the DUX total score and the selected TACQOL and
TAAQOL domains were statistically significant (all correlations
ranging between 0.34 and 0.55, P< 0.05), except for the social scale
of the TACQOL. The relationship between the Bt-DUX and the
selected health concept scales of the SF-36 was moderate with
Spearman correlation coefficients ranging between 0.41 and 0.49
(P< 0.01). The relationship from the Bt-DUX total score with the
PCS and MCS was not statistically significant. The Bt-DUX total
score was moderately related with functional limitations as
estimated with the TESS (Spearman’s r¼ 0.49; P< 0.01).
The DUX-Bt domain scores correlated well with their
corresponding domains of the other measures. The physical domain
score was moderately to strongly associated with the motor function
and autonomy scales of the TACQOL, gross motor functioning and
daily activities of the TAAQOL, the PCS scale and physical
functioning scale of the SF-36, and the TESS score (r¼ 0.40–0.65,
P< 0.01). The emotional domain score was moderately associated
with the pain and vitality scales of the TAAQOL and the MCS scale
and vitality scale of the SF-36 (r¼ 0.40–0.53, P< 0.05). The social
domain score was moderately associated with the social scales of the
TAAQOL and SF-36 (r¼ 0.34–0.49, P< 0.05), but showed no
significant relationship with the social domain of the TACQOL. The
cosmetic domain score of the DUX-Bt has no comparable score in
the other measures.
Discriminant Validity
Table VI illustrates the discriminating properties of the Bt-DUX
total score and the four domain scores regarding two categories of
the TESS (division made according to the median TESS score). It
was found that the Bt-DUX and all of its domain scores were
significantly higher in the patients with a better TESS scores
(P< 0.05).
DISCUSSION
In this cross-sectional study among patients with a malignant
bone tumor of the lower extremity, it was found that a newly
developed disease-specific instrument on patients’ valuations of
their lives, the Bt-Dux, was practically applicable, had sufficient
internal consistency, and a good construct and discriminant validity.
The mean scores of the TESS, TAAQOL, TACQOL, and SF-36 as
found in the present study are comparable to those found in other
studies [2–10], suggesting that our population is representative for
young patients’ shortly after surgery due to a malignant bone tumor in
the leg. The relativelyhigh percentage of patients after ablative surgery
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could probably be explained by the young age of our patients at
surgery, which makes endoprosthetic surgery less feasible, our choice
to classify rotationplasty as ablative surgery, and the number of
patients who underwent limb ablation as secondary surgery.
The Bt-DUX appeared to be a practically applicable instrument
with easily understandable questions and answer possibilities,
which could be completed in a short time notice. The question in the
Bt-DUX that was most frequently left unanswered, concerned
relations and/or sexuality. This low response rate could possibly be
explained by the relatively low average age of the patients.
The measurement properties of the Bt-DUX appeared to be
good, as the total score varying considerably and no floor or ceiling
effects were seen. Moreover, the internal consistency of both the
total and domain scores appeared to be sufficient [22].
In this study, the discriminating properties of the Bt-DUX were
studied by comparing Bt-DUX scores between two groups of
patients with different levels of physical function as classified by the
TESS score, showing good discriminating properties. Discriminat-
ing properties of the Bt-DUX with respect to different surgical
intervention groups still have to be determined.
The significant correlations between the Bt-DUX and measures
of functional ability and selected scales for QoL and its discrim-
inative abilities regarding patients with better or worse functional
ability support the construct validity of the Bt-DUX. As the
strengths of the correlations between the Bt-DUX and the other
instruments within the functional ability and QoL domains were
moderate to large, it is conceivable that the Bt-DUX evaluates a
different aspect of QoL, namely the patients’ individual values of
their life after the surgical intervention, including cosmetics and
sports. However, it remains to be established whether this instru-
ment may have an additional value above the other measures
commonly employed in this patient group.
The significant associations of the Bt-DUX with the other
instruments for QoL and functional ability together with the
discriminating properties of the instrument warrant further research
into its value for use in both scientific and clinical settings. Focusing
on the patient point of view is very relevant in today’s society in
which health care requires patients’ consent and active participation
[25]. The value that a person assigns to different aspects of daily
living (e.g., social, emotional, physical functioning, or cosmetical
contentment) influences the impact of changes due to the surgical
intervention. It is generally held that ablative surgery allows patients
to undertake more intensive physical activities and sports but that
limb salvage is more cosmetically appealing. It is conceivable that
patients differ with respect to their preferences for either sportive
achievements and functional ability or the cosmetic result [8]. In the
Pediatr Blood Cancer DOI 10.1002/pbc
TABLE III. Measures of Quality of Life and Functional Ability in 72 Patients Who Underwent
Surgical Treatment for a Malignant Bone Tumor of the Lower Extremity
N
Mean
(SD)
Median
(range)
Health-Related Quality of life
TACQOL-CF Motor 30 62.4 (12.6) 63 (20–88)
Child form Autonomy 74.3 (7.6) 75 (60–100)
Range 0–100 Social 74.5 (7.5) 76 (53–95)
TAAQOL Gross motor functioning 42 70.0 (23.7) 75 (6–100)
Adolescent form Pain 76.7 (23.1) 81 (13–100)
Range 0–100 Social functioning 89.7 (22.5) 100 (13–100)
Daily activities 76.3 (25.3) 88 (0–100)
Vitality 66.1 (21.9) 67 (8–100)
SF–36 PCS 41 35.3 (13.9) 37 (2–58)
Range 0–100 MCS 55.8 (13.6) 58 (9–75)
Functional Ability
TESS 72 85.3 (12.2) 89 (51–100)
Range 0–100
SF-36, Short Form 36; PCS, Physical Component Summary Score; MCS, Mental Component Summary
Score.
Fig. 1. Median scores and distribution of the Bt-DUX total and
domain scores. [Color figure can be viewed in the online issue, which is
available at www.interscience.wiley.com.]
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clinical setting, these preferences should be taken into account by
the decision on a surgical intervention. In addition, the Bt-DUX
could probably be useful to identify those patients who are strikingly
unhappy with one or more aspects of their life after surgery, with the
institution of subsequent interventions or support to cope with their
condition and its treatment. The results of our exploratory study
indicate that further research into the clinical value of the Bt-DUX is
warranted.
A limitation of this study is the relatively small number of
patients and the possible selection bias. Despite the fact that we
included five centers, the choice for specific types of surgery may
not be similar to those in other centers or countries. Due to the small
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TABLE IV. Mean and Median Item Scores of the Bt-DUX
Bt-DUX Mean Median Range Corresponding feeling
Emotional
How it’s going with me 1.6 1.0 1–4 Very happy
My life now 1.9 2.0 1–5 Happy
Other people 2.2 2.0 1–4 Happy
My health 2.1 2.0 1–5 Happy
My future 1.9 2.0 1–5 Happy
Social
Getting a relationship 1.9 2.0 1–5 Happy
People at school/work 2.0 2.0 1–5 Happy
Making new (girl)friends 1.6 1.0 1–3 Very happy
The things I do 1.8 2.0 1–4 Happy
My friends 1.6 1.0 1–3 Very happy
Cosmetically
How my leg looks like 1.9 2.0 1–5 Happy
How my walking looks like 2.2 2.0 1–5 Happy
The way people look at me 2.5 3.0 1–5 Ordinary
My appearance/the way I look 2.2 2.0 1–5 Happy
About myself 1.9 2.0 1–5 Happy
Functional
My ability in sport activities 3.2 3.0 1–5 Ordinary
The amount of sport I can do 3.1 3.0 1–5 Ordinary
Abilities at school/work 2.0 2.0 1–5 Happy
My stamina 2.9 3.0 1–5 Ordinary
The things I can’t do 3.8 4.0 1–5 Rather sad
TABLE V. Spearman Correlation Coefficients Between the Domain and Total Bt-DUX Scores and
Measures of Quality of Life and Functional Ability
Bt-DUX
Total Social Emot. Cosm. Physic.
TACQOL-CF
Motor functioning 0.40* 0.26 0.35 0.29 0.48**
Autonomy 0.55** 0.49** 0.43* 0.41* 0.50**
Social 0.14 0.11 0.12 0.14 0.18
TAAQOL
Gross motor 0.55** 0.38* 0.38* 0.50** 0.65**
Pain 0.48** 0.30 0.53** 0.33* 0.49**
Social 0.34* 0.34* 0.24 0.35* 0.23
Daily activities 0.55** 0.46** 0.48** 0.43** 0.53**
Vitality 0.46** 0.29 0.45** 0.48** 0.42**
SF-36
Physical functioning 0.41** 0.29 0.31 0.40* 0.52**
Social functioning 0.49** 0.49** 0.49** 0.31 0.36*
Vitality 0.47** 0.41** 0.47** 0.45** 0.36*
General health 0.43** 0.27 0.54** 0.47** 0.43**
PCS 0.26 0.14 0.22 0.23 0.40**
MCS 0.25 0.21 0.40* 0.10 0.14
TESS 0.49** 0.33** 0.43** 0.34** 0.59**
PCS, Physical Component Summary Score; MCS, Mental Component Summary Score; underlined and
bold, association expected between these domain scores. *Correlation is significant at the 0.05 level;
**Correlation is significant at the 0.01 level.
Quality of Life After Malignant Bone Tumor Surgery 353
sample size and the cross-sectional design of the study no estimation
of the effect of maturation can be made. Patients with a malignant
bone tumor may start as early teens and turn into adults during and
after the initial treatment. During this dynamic time in development,
ideas, goals, and responses may typically change. Moreover, the
ability of the instrument to show differences between different
surgical interventions groups or tibia versus femur lesions, and its
validity in patients in various stages of the disease, including the
first year where surgical and drug treatment is intensive and may
lead to complications, need to be further determined. To study these
factors in greater detail, a large population and a prospective study
design, preferably including multiple centers from different
countries, is needed. These limitations indicate that the validity of
the Bt-DUX in other populations and in other languages (e.g.,
English) still needs to be established.
In summary, the Bt-DUX is a practical and valid instrument
measuring patients’ individual QoL values after surgery due to a
malignant bone tumor in the leg. Its added value with respect to its
clinical and scientific usage needs to be further established.
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